Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press68210.17650/2219-4614-2024-16-3-19-23REVIEWSОБЗОРНЫЕ СТАТЬИOmics technologies in diagnosis and treatment of soft tissue sarcomasОмиксные технологии в диагностике и лечении сарком мягких тканейhttps://orcid.org/0009-0000-4830-9822AfoninaT. S.АфонинаТ. С.
Russian Federation

Tatyana Sergeevna Afonina

3 2nd Botkinskiy Proezd, Moscow 125284

 

Татьяна Сергеевна Афонина 

125284 Москва, 2-й Боткинский пр-д, 3

dyajouritta@yandex.ruhttps://orcid.org/0000-0002-2976-8895BukharovA. V.БухаровА. В.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

 

125284 Москва, 2-й Боткинский пр-д, 3

https://orcid.org/0000-0003-4927-5585FedenkoA. A.ФеденкоA. А.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

https://orcid.org/0000-0002-4385-9048DerzhavinV. A.ДержавинВ. А.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

https://orcid.org/0000-0003-2706-4138AlievM. D.АлиевМ. Д.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России1309202416319231109202411092024Copyright ©; 2024, Afonina T.S., Bukharov A.V., Fedenko A.A., Derzhavin V.A., Aliev M.D.Copyright ©; 2024, Афонина Т.С., Бухаров А.В., Феденко A.А., Державин В.А., Алиев М.Д.2024Afonina T.S., Bukharov A.V., Fedenko A.A., Derzhavin V.A., Aliev M.D.Афонина Т.С., Бухаров А.В., Феденко A.А., Державин В.А., Алиев М.Д.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/682

Currently, stratification of recurrence risk and prognosis of 5-year survival of patients with soft tissue sarcomas are primarily based on histological tumor classification. Drawing from these data, international oncological societies have proposed a hypothesis about development of gene expression profiling and molecular and genetic diagnosis technologies which will allow to more accurately assess risks of soft tissue sarcoma development and select individual drug treatment.

Стратификации рисков рецидивирования и прогноз 5-летней выживаемости пациентов с саркомами мягких тканей в настоящее время преимущественно опираются на гистологическую классификацию опухолей. На основе этих данных мировые онкологические сообщества выдвинули гипотезу о развитии технологий профилирования экспрессии генов и молекулярно-генетической диагностики, с помощью которых появится возможность более точно оценить риски развития сарком мягких тканей, а также подобрать индивидуальное лекарственное лечение.

soft tissue sarcomasomics technologiessoft tissue sarcoma treatmentsoft tissue sarcoma diagnosisсаркомы мягких тканейомиксные технологиилечение саркомы мягких тканейдиагностика саркомы мягких тканейBurns J., Brown J.M., Jones K.B., Huang P.H. The Cancer Genome Atlas: impact and future directions in sarcoma. Surg Oncol Clin N Am 2022;31(3):559–68. DOI: 10.1016/j.soc.2022.03.013Teramura Y., Tanaka M., Yamazaki Y. et al. Identification of novel fusion genes in bone and soft tissue sarcoma and their implication in the generation of a mouse model. Cancers 2020;12(9):1–15. DOI: 10.3390/cancers12092345Yoo B.C., Kim K.H., Woo S.M., Myung J.K. Clinical multi-omics strategies for the effective cancer management. J Proteomics 2018;188:97–106. DOI: 10.1016/j.jprot.2017.08.010Zagars G.K., Ballo M.T., Pisters P.W. et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003;97(10):2530–43. DOI: 10.1002/cncr.11365Cardoso F., Kyriakides S., Ohno S. et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(8):1194–220. DOI: 10.1093/annonc/mdz173Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst 2009;101(21):1446–52. DOI: 10.1093/jnci/djp335Pervaiz N., Colterjohn N., Farrokhyar F. et al. A systematic metaanalysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113(3):573–81. DOI: 10.1002/cncr.23592Kang H.J., Park J.H., Chen W. et al. EWS-WT1 oncoprotein activates neuronal reprogramming factor ASCL1 and promotes neural differentiation. Cancer Res 2014;74(16):4526–35. DOI: 10.1158/0008-5472.CAN-13-3663Kang H.J., Park J.H., Chen W. et al. EWS-WT1 oncoprotein activates neuronal reprogramming factor ASCL1 and promotes neural differentiation. Cancer Res 2014;74(16):4526–35. DOI: 10.1158/0008-5472.CAN-13-3663Halcrow P.W., Dancer M., Panteah M. et al. Molecular changes associated with tumor initiation and progression of soft tissue sarcomas: targeting the genome and epigenome. Prog Mol Biol Transl Sci 2016;144:323–80. DOI: 10.1016/bs.pmbts.2016.10.001Zou Z., Sun W., Xu Y. et al. Application of multi-omics approach in sarcomas: a tool for studying mechanism, biomarkers, and therapeutic targets. Front Oncol 2022;12:946022. DOI: 10.3389/fonc.2022.946022Zou Z., Sun W., Xu Y. et al. Application of multi-omics approach in sarcomas: a tool for studying mechanism, biomarkers, and therapeutic targets. Front Oncol 2022;12:946022. DOI: 10.3389/fonc.2022.946022Miyata T., Sonoda K., Tomikawa J. et al. Genomic, epigenomic, and transcriptomic profiling towards identifying omics features and specific biomarkers that distinguish uterine leiomyosarcoma and leiomyoma at molecular levels. Sarcoma 2015;2015:412068. DOI: 10.1155/2015/412068Yang J., Eddy J.A., Pan Y. et al. Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. Mol Cell Proteomics 2010;9(11):2405–13. DOI: 10.1074/mcp.M110.000240Chen K., Zhu C., Cai M. et al. Integrative metabolome and transcriptome profiling reveals discordant glycolysis process between osteosarcoma and normal osteoblastic cells. J Cancer Res Clin Oncol 2014;140(10):1715–21. DOI: 10.1007/s00432-014-1719-yFatokun A.A., Hunt N.H., Ball H.J. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids 2013;45(6):1319–29. DOI: 10.1007/s00726-013-1602-1Conrad D.F., Pinto D., Redon R. et al. Origins and functional impact of copy number variation in the human genome. Nature 2010;464(7289):704–12. DOI: 10.1038/nature08516Bilyaletdinova D.I., Kovalenko S.G., Spichak I.I. A clinical case of a tumor of the Ewing sarcoma family (primitive neuroectodermal tumor) of rare localization in the parietal bone. Pediatricheskiy vestnik Yuzhnogo Urala = Pediatric Bulletin of the Southern Urals 2015;2:70–5. (In Russ.).Билялутдинова Д.И., Коваленко С.Г., Спичак И.И. Клинический случай опухоли семейства саркомы Юинга (примитивной нейроэктодермальной опухоли) редкой локализации в теменной кости. Педиатрический вестник Южного Урала 2015;2:70–5.Semenova A.I. Ewing’s sarcoma and peripheral primitive neuroectodermal tumors (clinic, diagnosis, treatment). Prakticheskaya onkologiya = Practical Oncology 2005;6(4):234–9. (In Russ.).Семенова А.И. Саркома Юинга и периферические примитивные нейроэктодермальные опухоли (клиника, диагностика, лечение). Практическая онкология 2005;6(4):234–9.Katschnig A.M., Kauer M.O., Schwentner R. et al. EWS-FLI1per-EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma. Oncogene 2017;36(43):5995–6005. DOI: 10.1038/onc.2017.202Horbach L., Sinigaglia M., Da Silva C.A. et al. Gene expression changes associated with chemotherapy resistance in Ewing sarcoma cells. Mol Clin Oncol 2018;8(6):719–24. DOI: 10.3892/mco.2018.1608Casali P.G., Abecassis N., Aro H.T. et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(4):iv51–67. DOI: 10.1093/annonc/mdy096Sturm G., Finotello F., Petitprez F. et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immunooncology. Bioinformatics 2019;35:i436–45. DOI: 10.1093/bioinformatics/btz363Sturm G., Finotello F., Petitprez F. et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immunooncology. Bioinformatics 2019;35:i436–45. DOI: 10.1093/bioinformatics/btz363Yuan B., Ji W., Xia H., Li J. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma. Mol Med Rep 2018;17(3):4291–8. DOI: 10.3892/mmr.2018.8418Yuan B., Ji W., Xia H., Li J. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma. Mol Med Rep 2018;17(3):4291–8. DOI: 10.3892/mmr.2018.8418Wagner L.M., Crews K.R., Iacono L.C. et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10(3):840–8. DOI: 10.1158/1078-0432.ccr-03-0175Burdach S., Jürgens H. High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Critical Rev Oncol Hematol 2002;41(2):169–89. DOI: 10.1016/s1040-8428(01)00154-8Ladenstein R., Pötschger U., Le Deley M.C. et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010;28(20):3284–91. DOI: 10.1200/JCO.2009.22.9864Ladenstein R., Pötschger U., Le Deley M.C. et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010;28(20):3284–91. DOI: 10.1200/JCO.2009.22.9864Uren A., Toretsky J.A. Ewing’s sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol 2005;1(4):521–8. DOI: 10.2217/14796694.1.4.521Uren A., Toretsky J.A. Ewing’s sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol 2005;1(4):521–8. DOI: 10.2217/14796694.1.4.521Anderson P., Skubitz K., Miller R. et al. Activity of SCH 717454 in subjects with relapsed osteosarcoma or Ewing’s sarcoma (study P04720). In: Proceedings of the 14th Annual Meeting of the Connective Tissue Oncology Society (CTOS’07). November 2007. London, UK. Abstract #35094.Zhang B., Yang L., Wang X., Fu D. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses. Gene 2021;764:145105. DOI: 10.1016/j.gene.2020.145105